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Strengths and limitations of this study
 ► First trials within cohort (TwiCs) study design for 
bladder cancer.
 ► TwiCs design generates a wide variety of research 
opportunities with limited risk to patients.
 ► The non-interventional nature of this study means 
that patient participation may not benefit patients’ 
bladder cancer prognosis or quality of life.
AbStrACt
Introduction Given the need for more bladder cancer 
research and the recently observed advantages of 
introducing the trials within cohort (TwiCs) design, the 
set-up of the Graham Roberts Study (Roberts Study) will 
provide valuable infrastructure to answer a wide variety 
of research questions of a clinical, mechanistic, as well as 
supportive care nature in the area of bladder cancer.
Methods Using the TwiCs design, we will recruit patients 
aged 18 or older who are willing and able to provide 
signed informed consent and have a diagnosis of new 
or recurrent bladder cancer into this prospective cohort 
study. All patients must have a basic understanding of the 
English language. The following questionnaires will be 
collected at baseline and every 12 months subsequently: 
Functional Assessment of Chronic Illness Therapy for 
Bladder Cancer, the Functional Assessment of Chronic 
Illness Therapy-Fatigue, the Patient Heath Questionnaire-9, 
the standardised instrument for a generic health status 
(EQ-5D-5L), a Short Questionnaire to Assess Health-
Enhancing Physical Activity and the Hertfordshire Short 
Questionnaire to Assess Diet Quality.
Ethics and dissemination Due to the nature of this study, 
we obtained full ethical clearance from the London—
Fulham Research Ethics Committee (17/LO1975). All 
participants must provide full informed consent before 
recruitment onto the study. The results of this study will 
be published in peer-reviewed journals and data collected 
as part of the study will be made available to potential 
collaborators on an application basis.
bACkground
Bladder cancer is the seventh most common 
cancer in the UK, with about 10,400 patients 
diagnosed annually1; about 50% of patients 
will survive their cancer for 10 years or more 
after diagnosis. For the majority of patients, 
the disease remains indolent following initial 
treatment, and invasive and burdensome 
surveillance is required to mitigate the high 
risk of recurrence.2 However, there is propor-
tionally less research into bladder cancer 
compared with breast, prostate or kidney 
cancer.3 To provide the most efficient and 
high impact research strategy for patients 
with bladder cancer in the UK, we have estab-
lished a prospective cohort study of newly 
diagnosed patients with bladder cancer to 
allow research that can efficiently address 
clinical, mechanistic, as well as supportive 
care-related questions.
The design of this bladder cancer cohort 
study is similar to the Utrecht cohort for 
Multiple BREast cancer intervention studies 
and Long-term evaLuAtion,4 which is based 
on the trials within cohort (TwiCs) design 
introduced by Relton et al5 at the University of 
Sheffield in 2010. It is the first TwiCs design 
study in the area of bladder cancer.
The use of TwiCs has grown substantially in 
the last few years, with several new initiatives 
in the UK. TwiCs, originally introduced as 
cohort multiple randomised controlled trial 
(RCT) design, was introduced to address the 
problems associated with existing approaches 
for trials informing routine clinical practice.5 
Such shortcomings relate to recruitment, 
ethics, patient preferences and treatment 
comparisons. At least six TwiCs studies are 
currently ongoing in the UK.6
The Roberts Study will serve as a facility for 
multiple trials and follows the TwiCs design.
The main objectives of the Graham Roberts 
Study (Roberts Study) are:
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 ► To create a prospective cohort study of well-charac-
terised patients with bladder cancer, which provides 
the opportunity to conduct a variety of observational 
studies.
 ► To create the infrastructure for future RCTs that will 
allow more efficient recruitment using patient-cen-
tred informed consent.
MEthodS/dESIgn
twiCs design
The TwiCs design can be described as follows: initially, 
an observational cohort of patients with the condition 
of interest is recruited and their characteristics and 
outcomes measured longitudinally. Then, for each subse-
quent RCT, eligible patients from the cohort are identi-
fied using the collected longitudinal information. Eligible 
patients are randomised, and those selected are offered 
the trial intervention. Comparisons are then drawn 
between the outcomes of the randomly selected patients 
and the eligible patients not randomly selected, that is, 
those receiving usual care. This process can be repeated 
for future RCTs within the cohort.5
Longitudinal observational studies are characterised by 
the recruitment and regular follow-up of a large cohort 
of patients. The TwiCs design, however, is unique as all 
patients within the cohort consent at the outset to provide 
data to further investigate the benefits of treatments or 
interventions for the condition of interest. The study 
design holds capacity to develop multiple RCTs using 
patients from the same cohort. Indeed, the similarity 
of this approach to patient-centred informed consent 
offers a solution to the ethical criticisms of the traditional 
randomised consent designs.5
graham roberts Study
Patients will be recruited at Guy’s and St Thomas’ (GSTT) 
National Health Service (NHS) Foundation Trust, 
London, UK. All patients will be eligible for the study 
following their first visit for a new or recurrent bladder 
cancer diagnosis. Patients with limited understanding of 
the English language and patients under the age of 18 
years are ineligible. Since GSTT NHS Foundation Trust is 
a referral centre, the Roberts Study will include patients 
from various secondary and tertiary hospitals located 
across the UK. Each year, approximately 100 eligible 
patients visit the Urology Centre of GSTT for bladder 
cancer management.
All eligible patients who have already undergone diag-
nostic investigations and been informed about a (highly 
likely) bladder cancer will receive detailed written 
information about the Roberts Study while attending 
the Urology Centre for their initial appointment. They 
will be scheduled to see a member of the direct clinical 
care team and a research nurse/assistant 30 min prior 
to their first appointment with the consultant (urology 
or oncology). During this research consultation, the 
research nurse/assistant will explain the study in detail 
and written informed consent will be obtained from 
those who agree to participate. Such consent will be 
gained to allow:
 ► Participation in the Graham Roberts Study cohort 
and longitudinal study.
 ► The participant to be approached to participate in the 
intervention arm of any future RCT.
 ► The participant to be randomised to the control arm 
of any future RCT without knowledge of this status.
 ► Collection and storage of participants biological 
samples, including blood, urine and tissue, within the 
KHP Bladder Cancer Biobank.
 ► Linkage and use of participants routinely collected 
clinical data as recorded in electronic patient records.
At the time of full informed consent, the patients will 
also be provided with the study baseline questionnaire 
and asked to complete this at a convenient time.
For those eligible patients who have not yet been 
informed about their bladder cancer diagnosis at the 
time of visiting the Urology Centre, detailed written 
information about the Roberts Study will be provided 
by a research nurse/assistant after they have met with 
the consultant. If the patients are not ready to discuss 
this study in further detail at this point, a follow-up call 
will be made 1 week later to obtain their consent, if they 
have agreed to participate. Full written informed consent 
is subsequently obtained at the patients next clinical 
appointment.
Data from all patients may be used for observational 
studies in the Roberts Study, but only those who provide 
consent for randomisation are eligible for participation 
in the RCTs within the Roberts Study.
Thus, the TwiCs design is based on an ‘asymmetric 
informed consent’. After recruitment into the Roberts 
cohort, the randomisation of eligible subjects can be 
followed by an asymmetric treatment of the two arms; 
those selected for the experimental arm provide informed 
consent for the intervention trial, while the data from the 
control arm are used based on prior broad permission. 
Hence, the cohort participants are informed about future 
research within the cohort.
Selection and withdrawal of subjects
Patients eligible to participate in this study are those who 
meet all of the following inclusion criteria:
 ► Appointment for a new or recurrent diagnosis of 
bladder cancer at GSTT’ NHS Foundation Trust.
 ► Minimum age of 18 years.
 ► Basic understanding of English.
Patients will be identified in multidisciplinary team 
meetings or in outpatient clinics by the clinical team, in 
collaboration with the research nurse. Participants have 
the right to withdraw from the study at any time for any 
reason. Their routine medical and surgical care will not 
be affected.
Expected duration of the study and sample size
As this study is an observational prospective cohort study, 
it is difficult to estimate its duration. We aim to recruit a 
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Table 1 Data collection for those participants of the Roberts Study undergoing radical cystectomy
Preoperative TNM stage, weight, height, BMI, American Society of Anesthesiologists score, previous pelvic surgery, 
radiation or neoadjuvant chemotherapy
Perioperative Type of surgery, type of lymphadenectomy, type of urinary diversion, blood loss, duration of surgery, 
accidental organ injury during surgery
Postoperative Complications (Clavien-Dindo), reoperations and readmissions within 90 days, length of hospital stay, pT 
stage, number of excised lymph nodes and number of excised and metastatic lymph nodes
BMI, body mass index.
minimum of 400 patients over a period of 5 years, though 
there is no limit to the number of patients needed for 
a prospective cohort study. Moreover, over time, new 
research opportunities will develop and potential 
funding may become available to continue recruitment 
into the Roberts Study. Patients will be followed up for 
life through data linkages with Hospital Episode Statistics 
(HES), the Office for National Statistics (ONS) and elec-
tronic patient records.
As this is a prospective cohort study, with no specific 
primary research question, it is not possible to perform 
sample size calculations. However, it is still important 
to consider recruitment rates and response rates to the 
questionnaires.
Recruitment to the Graham Roberts Study commenced 
on 23 March 2018. At the point of submission of this 
protocol (April 2019), 84 patients with bladder cancer 
had been approached with a patient information sheet, 
and 72 patients had provided full written informed 
consent and completed the baseline study questionnaire. 
At current rates of consent, the authors project the base-
line recruitment of 400 patients with bladder cancer to 
be completed by 31 August 2023. It is expected, however, 
that recruitment rates will increase as the direct clinical 
care team and research nurses/assistants become more 
efficient at identifying and approaching eligible patients. 
The projected end of recruitment date is therefore set 
at 31 December 2022. Moreover, ethical clearance is in 
place to recruit until this date.
data collection
Within the Roberts Study, various clinical data will be 
prospectively collected including demographics, tumour 
characteristics, treatment and CT and MRI imaging data. 
Clinical data will be captured from electronic medical 
records, referral letters and annual reports for Public 
Health England.
Sociodemographic data will include sex, date of birth, 
age at diagnosis, highest level of education, postal code 
(to estimate the deprivation index), body mass index and 
WHO performance status.
The following tumour characteristics will be collected: 
the TNM classification of malignant tumours, stage, 
grade, tumour diameter, number of tumours, histology 
and morphological codes and invasiveness.
Treatment characteristics comprise data on type and 
timing of treatment given (eg, intravesical instillations, 
systemic chemotherapy, radical cystectomy, radiotherapy 
or other treatments). Additional detailed data, as reported 
in surgical notes, will be available for those patients with 
bladder cancer who undergo radical cystectomy. Table 1 
illustrates the preoperative, perioperative and postop-
erative variables which will be collected for this patient 
subset.
Information on disease progression, recurrence and 
survival will be collected annually by means of the data 
linkages with HES, ONS and electronic patient records. 
We will also collect patient-reported outcome measures 
(PROMs) by means of validated questionnaires designed 
to quantify health-related quality of life (QoL) from the 
patients’ perspective. These questionnaires will be given 
(paper (post) or digital (email or tablet in clinic)) to 
patients on entry into the cohort (baseline) and every 
12 months thereafter with a total follow-up of at least 10 
years. It will take about 30 min to fill out the set of ques-
tionnaires at each time point.
PROMs will be collected on QoL, fatigue, anxiety and 
depression, physical activity, dietary habits as well as risk 
behaviour in terms of known bladder cancer risk factors. 
Following an assessment of smoking behaviour, alcohol 
consumption and occupational bladder cancer risk 
factors, the following validated questionnaires will be 
used (see online supplementary additional file 1):
 ► QoL: Functional Assessment of Chronic Illness 
Therapy for Bladder Cancer.7
 ► Fatigue: Functional Assessment of Chronic Illness 
Therapy-Fatigue.8
 ► Depression: Patient Health Questionnaire-9.9
 ► Health: Standardised instrument for use as a measure 
of health outcome (EQ-5D-5L10).
 ► Physical activity: Short Questionnaire to Assess 
Health-Enhancing Physical Activity.11
 ► Assessment of dietary habits: Short Questionnaire to 
Assess Diet Quality.12
Assessment of safety
As this is a prospective cohort study with no specific 
interventions, adverse events (AEs) are unlikely to take 
place. Nevertheless, if filling out questionnaire data 
should ever result in an AE, it will be graded according 
to the National Cancer Institute Common Terminology 
Criteria for Adverse Events Version 4.0 and coded. These 
will be reported to the Data Monitoring Committee 
(DMC).
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Given that we see on average about 100 eligible patients 
per year, we expect to recruit at least 400 patients over a 
period of 5 years. However, as described above, if more 
research and/or funding opportunities come up, we will 
continue recruitment into the Roberts Study.
Patient and public engagement
The development of the Graham Roberts Study was 
informed in collaboration with patient representatives 
diagnosed and treated at GSTT’ NHS Foundation Trust. 
Prior to development of the study protocol, a focus group 
was held to discuss the acceptability of the TwiCs study 
design and the content of the self-administered ques-
tionnaire. Patients of similar bladder cancer diagnoses to 
those that will be consented onto the study were recruited 
into this focus group. Based on the patient’s experiences 
and preferences, the Graham Roberts Study design was 
agreed. Results of the study will be disseminated to the 
patients through annual newsletters and on a study-spe-
cific website for patients.
direct access to source data and documents
The investigator will prepare and maintain adequate 
and accurate source documents designed to record all 
observations and other pertinent data for each patient in 
the Roberts Study. Study personnel will enter data from 
source documents corresponding to a patient’s visit into 
the protocol-specific electronic case report forms (CRFs) 
in a dedicated, secure data warehouse. Patients will not be 
identified by name in the study database or on any study 
documents to be collected by the sponsor (or designee), 
but will be identified by patient ID numbers.
The database will be safeguarded against unautho-
rised access with established security procedures; nightly 
backup of the database and related software files will be 
maintained. At prespecified junctures of the protocol (eg, 
production of interim and final reports), data for analysis 
will be locked and cleaned as per established procedures.
If a correction is required to a CRF, the time and 
date stamps will track the person entering or updating 
CRF data and create an electronic audit trail. The chief 
investigator is responsible for reviewing all information 
collected on patients enrolled in this study for complete-
ness and accuracy.
To enable evaluations and/or audits from regulatory 
authorities, the CI agrees to keep records, including 
the identity of all participating subjects (sufficient infor-
mation to link records, for example, CRFs and hospital 
records), all original signed informed consent forms, 
safety reporting forms, source documents and detailed 
records of treatment disposition and adequate documen-
tation of relevant correspondence (eg, letters, meeting 
minutes, telephone call reports). The records should be 
retained by the CI according to the International Confer-
ence on Harmonisation or local regulations; all study 
documentation must be retained for 10 years after the 
study ends.
Quality assurance
Monitoring of this study will be performed to ensure 
compliance with Good Clinical Practice, and scientific 
integrity will be managed and oversight retained by the 
DMC led by Prof Dominique Michaud. The committee 
will receive notification every 6 months of the interim and 
total accrual. At the discretion of the chair of the DMC, 
interim analyses may be scheduled as modifications to the 
protocol. Additional meetings during the study period 
may occur at the discretion of the Steering Committee.
The study design, analysis and reporting will follow 
the recent recommendations for good practice in clin-
ical outcomes assessment by the International Society for 
Pharmacoeconomics and Outcomes Research.13
data handling
The chief investigator and delegates are responsible for 
daily cohort management. Data quality will be checked 
periodically. The following guidelines will be strictly 
adhered to:
 ► Patient data will be anonymised.
 ► All anonymised data will be stored on a password-pro-
tected encrypted computer.
 ► All study data will be stored in line with the Data 
Protection Act as defined in the King’s Health Part-
ners’ Clinical Trials Office Archiving SOP.
The data will be stored as outlined in the data manage-
ment plan.
Insurance/indemnity
The cosponsors King’s College London and GSTT’ NHS 
Foundation Trust will provide insurance and indemnity.
dISCuSSIon
The Graham Roberts Study is the first of its kind and thus 
the first TwiCs study for bladder cancer. It generates a 
wide variety of research opportunities with limited risk to 
patients. Participation in research involves some loss of 
privacy. We will do our best to make sure that all personal 
information gathered for this study is kept private. As this 
is a non-interventional prospective cohort study, participa-
tion may not have a beneficial effect on patients’ bladder 
cancer prognosis or QoL compared with usual care.
The questionnaires to be used are quite detailed and, 
for the most part, concerns day-to-day activities such as 
quality and duration of sleep, diet and exercise. The 
questionnaire does pose some more personal and intru-
sive questions however, including questions related to 
symptoms of depression. These questions can be omitted 
if the participant does not feel comfortable answering 
them. There is a risk that some participants may be upset 
by having these questions posed to them. Some partic-
ipants may prefer to complete the questionnaire them-
selves, whereas others may prefer to do so with a research 
assistant. Participants will be fully informed about these 
potential harms and enabled to make an informed 
decision regarding participation. We consider that the 
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potential minor harms are outweighed by the potential 
benefits of the research.
Future research using the data in this study could lead 
to medical and scientific products, discoveries, as well as 
interventions that improve the prevention, diagnosis and 
treatment of bladder cancer. A benefit for the patients is 
also the possibility to be part of future RCTs by providing 
consent for being part of the intervention arm.
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